LENZ
LENZ Therapeutics
LENZ
LENZ
105 hedge funds and large institutions have $542M invested in LENZ Therapeutics in 2025 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 30 increasing their positions, 27 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
105
Holders Change
+11
Holders Change %
+11.7%
% of All Funds
1.43%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
24
Increased
30
Reduced
27
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$19.1M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$14.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$13.8M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$3.2M |
| 5 |
SM
Scoggin Management
New York
|
+$2.57M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.3M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$11.8M |
| 3 |
State Street
Boston,
Massachusetts
|
-$5.32M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$4.32M |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$1.75M |
